ClinicalTrials.gg

Program

S-606001

A development code.

Its studies are mostly in Glycogen Storage Disease Type II, led by Shionogi.

Furthest: phase 2, since Jul 25, 20253 company-led studies, 3 open or runningNext primary completion: Aug 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogi33 open or runningphase 2since Jul 25, 2025Jul 25, 2025Aug 8, 2027phase 2 · NCT07123155

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 25, 2025First study: phase 2 study in Glycogen Storage Disease Type IIFirst studyNCT07123155 · 45 planned · United States, Belgium, Denmark and more
  2. Jul 30, 2026Phase 2 study in Glycogen Storage Disease Type IINCT07750990 · 60 planned
  3. Aug 24, 2026Phase 1 study in Glycogen Storage Disease Type IINCT07787650 · 15 planned

Ahead

  1. Aug 8, 2027Primary completion: phase 2 study in Glycogen Storage Disease Type IINCT07123155
  2. Aug 31, 2028Primary completion: phase 2 study in Glycogen Storage Disease Type IINCT07750990
  3. Oct 31, 2028Primary completion: phase 1 study in Glycogen Storage Disease Type IINCT07787650

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07787650Glycogen Storage Disease Type II1Not yet recruitingOct 31, 202815
NCT07750990Glycogen Storage Disease Type II2Not yet recruitingAug 31, 202860
NCT07123155Glycogen Storage Disease Type II · United States, Belgium, Denmark and more2RecruitingAug 8, 202745

How it is read

Names in the registry

  • “S-606001”, 3 entries

Codes read as this program: S606001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.